For advanced melanoma, 5-year overall survival reached 26% for anti-CTLA4 monotherapy, 44% for anti-PD1 monotherapy and 52% for the combined (anti-CTLA4 plus anti-PD1) treatment [1], yet a large proportion of patients exhibit primary resistance. Here, CTLA4 is linked to melanoma.